PROCEPT BioRobotics Names Larry L. Wood as New President, Reza Zadno to Retire

PROCEPT BioRobotics announced executive changes, with Larry L. Wood joining as president on September 2, 2025, and Dr. Reza Zadno retiring as president and director on September 1, 2025. Mr. Wood has over 40 years of experience in the medical technology industry and previously served as corporate vice president at Edwards Lifesciences. Dr. Zadno led the company through significant growth and commercial expansion since 2020.

Procept Biorobotics (Nasdaq: PRCT) has announced significant executive changes, with Larry L. Wood taking over as president and CEO on September 2, 2025, and Dr. Reza Zadno retiring as president and director on September 1, 2025. This transition comes as the company continues to grow and expand its innovative Aquablation therapy for treating prostate cancer [1].

Mr. Wood brings over 40 years of experience in the medical technology industry, having previously served as corporate vice president at Edwards Lifesciences. He will be leading the company through its next phases of growth, building on the success achieved under Dr. Zadno's leadership [2]. Dr. Zadno, who led Procept Biorobotics since 2020, has overseen significant growth and commercial expansion, including the successful commercialization of Aquablation therapy and the company's 2021 IPO [1].

Procept Biorobotics has also pre-announced strong second-quarter 2025 revenue of approximately $79.2 million, representing 48% annual growth. This growth underscores the company's continued momentum and the increasing adoption of its innovative Aquablation therapy [2]. The company's mission is to revolutionize BPH treatment globally by delivering best-in-class robotic solutions that positively impact patients and drive value.

In his new role, Mr. Wood will be responsible for continuing the company's mission to transform the standard of care for prostate disorders. He joins Procept Biorobotics with a deep understanding of the medical technology industry and a track record of driving innovation and growth. His appointment is seen as a strategic move to build on the company's recent successes and position it for future growth.

The leadership transition comes at a critical time for Procept Biorobotics, as it continues to expand its clinical trials and market reach. The company's Aquablation therapy has shown promise in treating prostate cancer and other urological conditions, and the appointment of Mr. Wood signals a commitment to further advancing this technology.

Procept Biorobotics will report its second-quarter 2025 earnings results after market close on Wednesday, August 6, 2025. The company's management will host a corresponding conference call at 4:30 p.m. Eastern Time to discuss the results [2].

References:
[1] https://www.massdevice.com/procept-ceo-retire-edwards-exec-succeed/
[2] https://www.stocktitan.net/news/PRCT/procept-bio-robotics-president-and-ceo-dr-reza-zadno-to-retire-57ez74d053fq.html